Key facts
- It has raised $50K; the latest was Angel (individual) ($50K) in Feb 2026.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for Lurex Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Lurex Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Lurex Bio
Developer of a biotechnology platform designed to enable the immune system to detect and attack abnormal cells. The company's platform includes engineered immune markers, controlled immune activation, and transient targeting mechanisms, enabling researchers and medical institutions to advance immune-focused treatments with improved precision, safety, and effectiveness for complex diseases.
- Sector
- Healthcare
- HQ
- Fort Lauderdale, FL, United States
- Founded
- 2025
- Website
- lurexbio.com/
- Ownership
- Privately Held (backing)
Lurex Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Lurex Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Lurex Bio in its N-PORT filings yet. We sweep new filings monthly.